372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC).
Despite therapeutic advances, VVC remains a common problem worldwide, affecting all strata of society and being
the second largest gynaecological infection. If it is left untreated, many complications have been appointed as its consequence, such
as infertility, subsequent preterm delivery, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, pelvic
abscess, menstrual disorders and miscarriage.
Avodes has developed an innovative medical device - a patented anatomically shaped “moist sponge” made of
completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal
microflora during most vulnerable period – menstruation. Unique Avodes biotechnological solution
preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It
inhibits Candida by 85 % thus treating and preventing the disease. Avodes effectively disrupts the vicious cycle of ”microbiota
disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance” and offers break-through solution which
protects women’s health and the environment.
Women Tech EU programme supported company in upgrading the business model, business and marketing plan, market
validation and helped to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful
project implementation provided much needed tailwind to our company to bring the product to the market.
